Consultancy Agreement with Voisin Consulting SARL

RNS Number : 3070A

Oxford Cannabinoid Tech.Holdings

01 June 2021

 

1 June 2021

OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC

("OCTP" or the "Company") 

Consultancy Agreement with Voisin Consulting SARL

Oxford Cannabinoid Technologies Holdings plc, a UK based pharmaceutical company focussed on developing cannabinoid-based prescription medicines approved by regulatory agencies is pleased to announce that on 28 May 2021, it entered into a new consultancy agreement with Voisin Consulting SARL (trading as Voisin Consulting Life Sciences) ("VCLS"), a consulting team with more than 200 professionals in the UK, Europe, US and India, with expertise in medical devices, cannabinoids, neurological disorders and addiction, in order to:

(1)  support and develop a regulatory strategy and roadmap for the UK and the US markets as a priority and consider potential subsequent delelopment in the EU;

(2)  provide a high level nonclinical gap analysis of the Company's development plan to support First Time in Humans (FTiH) clinical trials; and

(3)  provide a high level review of the Company's clinical development plan in relation to FTiH studies planned in patients;

in relation to the Company's drug development of lead compound OCT461201 in the areas of post-herpetic neuralgia and visceral pain due to irritable bowel syndrome.  

OCTP has previously engaged VCLS on regulatory matters relating to the development of its phytocannabinoid (an unmodified naturally occurring cannabinoid) drug candidate.

Dr John Lucas, Chief Executive Officer of OCTP, said:  "we are delighted to continue to partner with Voisin Consulting Life Sciences in our quest to deliver life-changing therapies for severe pain. OCT, which recently listed on the London Stock Exchange (LSE: OCTP), wants its innovative strategy to have the necessary depth in strength and quality which is crucial to deliver a much-needed product that is both safe and efficacious. Our management team is determined to do the right thing for its patients and we believe that a consultancy firm like VCLS can provide us with best-in-class support. As a consequence of our early discussions with the VCLS team, it became clear that their expertise, knowledge, and quality meant they were the partners we were looking for."

Emmanuelle M Voisin, Founder and CEO of Voisin Consulting Life Sciences, said: "we are thrilled to be partnering with Oxford Cannabinoid Technologies at this important stage, to support it on its exciting journey to become the global leader in developing cannabinoid-based prescription medicines. I am delighted that OCTP has chosen Voisin Consulting Life Sciences to facilitate its delivery of innovative, life-changing pain medication."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).

The Directors of the Company accept responsibility for the content of this announcement.

Enquiries

Oxford Cannabinoid Technologies Holdings plc   0 203 034 2820  

Dr John Lucas (CEO)      [e-mail]  

Clarissa Sowemimo-Coker (COO)    [e-mail]  

Cairn Financial Advisers - Financial Adviser   

Emily Staples   [phone]  

Jo Turner                                                  [phone]

Acuitas Communications   020 3848 2819

Simon Nayyar                                            [e-mail]  

James Gittings                                          [e-mail]    

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

 

END

 

 

AGRDZGFKGMRGMZZ